Niagen Bioscience (NAGE) Return on Capital Employed (2011 - 2026)
Niagen Bioscience's (NAGE) quarterly Return on Capital Employed came in at 14.94% in Q1 2026, down 957.0% year-on-year from 1.74% in Q1 2025, and down 24.4% on a QoQ basis from 19.77% in Q4 2025.
Niagen Bioscience (NAGE) Return on Capital Employed (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 14 years of Return on Capital Employed data on file, last reported at 14.94% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 957.0% year-over-year to 14.94% in Q1 2026; TTM through Mar 2026 was 14.94%, a 957.0% decrease from a year earlier, with the FY2025 full-year figure at 24.14%, up 645.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 14.94%, down from 19.77% in the prior quarter.
- Over the last five years, Return on Capital Employed for NAGE reached as high as 26.77% in Q3 2025 and fell as low as 88.23% in Q2 2022.
- Historically, Return on Capital Employed has averaged 16.75% across 5 years, with a median of 12.44% in 2024.
- Across the five-year window, Return on Capital Employed sank 1515 bps in 2022 and surged 6268 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 58.23% in 2022, then soared by 71 bps to 16.66% in 2023, then soared by 204 bps to 17.38% in 2024, then advanced by 14 bps to 19.77% in 2025, then dropped by 24 bps to 14.94% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 14.94% in Q1 2026, 19.77% in Q4 2025, and 26.77% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Niagen Bioscience | 253.47 Mn | 186.92 Mn | 19.98 Mn | 14.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.94% |
| Dec 31, 2025 | 19.77% |
| Sep 30, 2025 | 26.77% |
| Jun 30, 2025 | 26.00% |
| Mar 31, 2025 | 24.51% |
| Dec 31, 2024 | 17.38% |
| Sep 30, 2024 | 1.19% |
| Jun 30, 2024 | -6.36% |
| Mar 31, 2024 | -12.44% |
| Dec 31, 2023 | -16.66% |
| Sep 30, 2023 | -20.29% |
| Jun 30, 2023 | -25.55% |
| Mar 31, 2023 | -36.25% |
| Dec 31, 2022 | -58.23% |
| Sep 30, 2022 | -76.50% |
| Jun 30, 2022 | -88.23% |
| Mar 31, 2022 | -74.79% |
| Dec 31, 2021 | -65.18% |
| Sep 30, 2021 | -61.35% |
| Jun 30, 2020 | -111.27% |